India, Aug. 26 -- Aurobindo Pharma Ltd has announced that its wholly owned step-down subsidiary, CuraTeQ Biologics s.r.o., has received marketing authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for Dazublys™, its trastuzumab biosimilar.
This follows the European Commission's approval of Dazublys™ in July 2025. The product becomes CuraTeQ's fourth biosimilar to be cleared by the MHRA, after Bevqolva™ (December 2024), Zefylti™ (May 2025), and Dyrupeg™ (June 2025). Notably, Dazublys™, Zefylti™, and Dyrupeg™ have also secured marketing authorisations in the European Union.
Published by HT Digital Content Services with permission from Dion Global Solutions L...